JMP's Biotechnology Industry Overview

JMP Securities is not expecting much transformative clinical results at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Atlanta June 2 through June 6. Instead, analysts will be seeking incremental data from development programs that may impact several stocks positively. Several stocks believed to be underappreciated with possible value-added clinical data at ASCO include: at market outperform Celgene Corp., Human Genome Sciences Inc., Ariad Pharmaceuticals Inc., Genomic Health Inc., Cytokinetics Inc., Cytogen Corp., SGX Pharmaceuticals Inc., as well as NeoPharm Inc. (strong buy).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.